Adaptive and Collaborators to Present More than 30 Abstracts at 2023 ASH Annual Meeting

Read More

Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)